Radiesse™ calcium hydroxylapatite injectable filler

Nikita Gupta, Onir L. Spiegel, Jeffrey H. Spiegel

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


In December 2006, the Food and Drug Administration approved calcium hydroxylapatite (CaHA) as an injectable dermal filler for the correction of moderate to severe facial wrinkles and treatment for HIV lipoatrophy. Radiesse is often well received as a suggested filler because its primary active constituent, Calcium, is familiar to people and considered to be beneficial to overall health. Bruising is a potential side effect of any injection and Radiesse treatments are no exception. Radiesse, as a particulate injectable, has a risk of embolization if inadvertently injected in this fashion and complications such as vision loss or even blindness could occur in certain locations. Nasal irregularities such as a deep radix can be improved with Radiesse though great caution must be taken to prevent intravascular injection of the material with the risks of embolization and complications.

Original languageEnglish
Title of host publicationNeurotoxins and Fillers in Facial Esthetic Surgery
Number of pages4
ISBN (Electronic)9781119294306
StatePublished - Jan 19 2019

Bibliographical note

Publisher Copyright:
© 2019 John Wiley & Sons, Inc. All rights reserved.


  • Bruising
  • Calcium hydroxylapatite injectable filler
  • Intravascular injection
  • Nasal irregularities
  • Radiesse treatment

ASJC Scopus subject areas

  • Dentistry (all)


Dive into the research topics of 'Radiesse™ calcium hydroxylapatite injectable filler'. Together they form a unique fingerprint.

Cite this